Protein recombinant vaccine NVX-CoV2373 confers protection during Omicron dominant period in Italy

FHS
October 8, 2023
10:29 pm

The NVX-CoV2373 COVID-19 vaccine offers significant protection against symptomatic infections, but its effectiveness against SARS-CoV-2 declines within four months, according to a study in JAMA Network Open using Italian data. However, its protection against symptomatic COVID-19 seems to remain stable during this period.

Amgen and Horizon can close their $28B deal after resolving lawsuit by the FTC

Amgen has settled with the Federal Trade Commission after the US regulator in May had tried blocking the California drugmaker’s proposed nearly $28 billion acquisition

September 2, 2023

Medacta Group SA reports strong revenue growth at 21.4% at constant currency and adjusted EBITDA margin at 28.2% in the first semester 2023 – Biotech Investments

Medacta Group SA / Key word(s): Half Year Results/Half Year Results 22-Sep-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53

September 23, 2023

Combination immunotherapy yields 10-year survival for metastatic melanoma patients

Long-term data from a landmark international trial show about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free

September 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.